{"id":"https://openalex.org/W4311027674","doi":"https://doi.org/10.1002/cpdd.1208","title":"A Study to Evaluate Relative Bioavailability, Food Effect, and Pharmacodynamics of Tropifexor, a Farnesoid X Receptor Agonist, in Healthy Participants","display_name":"A Study to Evaluate Relative Bioavailability, Food Effect, and Pharmacodynamics of Tropifexor, a Farnesoid X Receptor Agonist, in Healthy Participants","publication_year":2022,"publication_date":"2022-12-10","ids":{"openalex":"https://openalex.org/W4311027674","doi":"https://doi.org/10.1002/cpdd.1208","pmid":"https://pubmed.ncbi.nlm.nih.gov/36495282"},"language":"en","primary_location":{"id":"doi:10.1002/cpdd.1208","doi":"https://doi.org/10.1002/cpdd.1208","is_oa":false,"landing_page_url":"https://doi.org/10.1002/cpdd.1208","pdf_url":null,"source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5064974711","display_name":"Rowan A. Stringer","orcid":"https://orcid.org/0000-0002-8404-6107","observed_orcids":["https://orcid.org/0000-0002-8404-6107"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH"],"is_corresponding":true,"raw_author_name":"Rowan Stringer","raw_affiliation_strings":["Novartis Institutes for BioMedical Research PK Sciences  Basel Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Institutes for BioMedical Research PK Sciences  Basel Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100457146","display_name":"Jin Chen","orcid":"https://orcid.org/0000-0001-7617-1664","observed_orcids":["https://orcid.org/0000-0001-7617-1664"]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jin Chen","raw_affiliation_strings":["Novartis Pharmaceuticals Corporation East Hanover  New Jersey USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation East Hanover  New Jersey USA","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000594102","display_name":"Bharti Shah","orcid":"https://orcid.org/0009-0006-1471-6116","observed_orcids":["https://orcid.org/0009-0006-1471-6116"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bharti Shah","raw_affiliation_strings":["Novartis Institutes for Biomedical Research East Hanover  New Jersey USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Institutes for Biomedical Research East Hanover  New Jersey USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103976259","display_name":"Jessie Gu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jessie Gu","raw_affiliation_strings":["Novartis Institutes for Biomedical Research  Cambridge Massachusetts USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Institutes for Biomedical Research  Cambridge Massachusetts USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100395360","display_name":"Yiming Zhang","orcid":"https://orcid.org/0000-0002-2224-006X","observed_orcids":["https://orcid.org/0000-0002-2224-006X"]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yiming Zhang","raw_affiliation_strings":["Novartis Pharmaceuticals Corporation East Hanover  New Jersey USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation East Hanover  New Jersey USA","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022472681","display_name":"William Prince","orcid":"https://orcid.org/0009-0000-5341-6382","observed_orcids":["https://orcid.org/0009-0000-5341-6382"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"William Prince","raw_affiliation_strings":["Novartis Institutes for Biomedical Research  Cambridge Massachusetts USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Institutes for Biomedical Research  Cambridge Massachusetts USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078607812","display_name":"Lloyd B. Klickstein","orcid":"https://orcid.org/0000-0002-4108-9123","observed_orcids":["https://orcid.org/0000-0002-4108-9123"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lloyd B. Klickstein","raw_affiliation_strings":["Novartis Institutes for Biomedical Research  Cambridge Massachusetts USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Institutes for Biomedical Research  Cambridge Massachusetts USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5005604593","display_name":"Ralph Woessner","orcid":"https://orcid.org/0000-0002-8719-6856","observed_orcids":["https://orcid.org/0000-0002-8719-6856"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Ralph Woessner","raw_affiliation_strings":["Novartis Institutes for BioMedical Research PK Sciences  Basel Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Institutes for BioMedical Research PK Sciences  Basel Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5064974711"],"corresponding_institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"],"apc_list":{"value":3350,"currency":"USD","value_usd":3350},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"12","issue":"2","first_page":"122","last_page":"131"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.37209999561309814,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.37209999561309814,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10256","display_name":"Drug Solubulity and Delivery Systems","score":0.3005000054836273,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.16189999878406525,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/farnesoid-x-receptor-agonist","display_name":"farnesoid X receptor agonist","score":0.9950000047683716},{"id":"https://openalex.org/keywords/relative-bioavailability","display_name":"relative bioavailability","score":0.9229999780654907},{"id":"https://openalex.org/keywords/food-effect","display_name":"food effect","score":0.9959999918937683},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8650000095367432},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9819999933242798},{"id":"https://openalex.org/keywords/fgf19","display_name":"FGF19","score":0.9760000109672546},{"id":"https://openalex.org/keywords/lipid-based-formulations","display_name":"lipid-based formulations","score":0.6710000038146973},{"id":"https://openalex.org/keywords/soft-gelatin-capsules","display_name":"soft gelatin capsules","score":0.8849999904632568},{"id":"https://openalex.org/keywords/drug-solubility","display_name":"drug solubility","score":0.6069999933242798},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.546999990940094}],"concepts":[{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.7963817119598389},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.7592067718505859},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7450364232063293},{"id":"https://openalex.org/C87813604","wikidata":"https://www.wikidata.org/wiki/Q1242899","display_name":"Crossover study","level":4,"score":0.7148953676223755},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6839627027511597},{"id":"https://openalex.org/C76318530","wikidata":"https://www.wikidata.org/wiki/Q16833590","display_name":"Area under the curve","level":2,"score":0.6701376438140869},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.6089388728141785},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.5198593735694885},{"id":"https://openalex.org/C40222840","wikidata":"https://www.wikidata.org/wiki/Q185049","display_name":"Geometric mean","level":2,"score":0.492664635181427},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.44374212622642517},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4308260977268219},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3951907157897949},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.30472642183303833},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.12639492750167847},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.09448781609535217},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.08225509524345398},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.0},{"id":"https://openalex.org/C105795698","wikidata":"https://www.wikidata.org/wiki/Q12483","display_name":"Statistics","level":1,"score":0.0},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000099150","descriptor_name":"Receptor, Farnesoid X-Activated","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007555","descriptor_name":"Isoxazoles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018565","descriptor_name":"Food-Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D052160","descriptor_name":"Benzothiazoles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1002/cpdd.1208","doi":"https://doi.org/10.1002/cpdd.1208","is_oa":false,"landing_page_url":"https://doi.org/10.1002/cpdd.1208","pdf_url":null,"source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},{"id":"pmid:36495282","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/36495282","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology in drug development","raw_type":"Randomized Controlled Trial"},{"id":"pmh:oai:oak.novartis.com:47542","doi":null,"is_oa":false,"landing_page_url":"https://oak.novartis.com/47542/","pdf_url":null,"source":{"id":"https://openalex.org/S4306400709","display_name":"The Novartis Repository (Novartis)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1283582996","host_organization_name":"Novartis (Switzerland)","host_organization_lineage":["https://openalex.org/I1283582996"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":26,"referenced_works":["https://openalex.org/W1886088333","https://openalex.org/W1954050093","https://openalex.org/W1963587340","https://openalex.org/W1966514588","https://openalex.org/W1970740746","https://openalex.org/W1985210677","https://openalex.org/W1989357395","https://openalex.org/W1997106286","https://openalex.org/W2005911243","https://openalex.org/W2015767901","https://openalex.org/W2022279737","https://openalex.org/W2061742628","https://openalex.org/W2079261283","https://openalex.org/W2087577664","https://openalex.org/W2106768039","https://openalex.org/W2334452059","https://openalex.org/W2519114186","https://openalex.org/W2612631436","https://openalex.org/W2769380893","https://openalex.org/W2784137104","https://openalex.org/W2883359071","https://openalex.org/W2946054531","https://openalex.org/W2994629683","https://openalex.org/W3045187805","https://openalex.org/W3157794914","https://openalex.org/W3208364643"],"related_works":["https://openalex.org/W2994629683","https://openalex.org/W4387661908","https://openalex.org/W1991518416","https://openalex.org/W1764647269","https://openalex.org/W4289977472","https://openalex.org/W4380987429","https://openalex.org/W2148572721","https://openalex.org/W4323037122","https://openalex.org/W4411452681","https://openalex.org/W2168901462"],"abstract_inverted_index":{"This":[0],"open-label,":[1],"randomized,":[2],"3-treatment,":[3],"3-period,":[4],"6-sequence,":[5],"crossover":[6],"study":[7],"in":[8,203],"healthy":[9],"subjects":[10],"compared":[11],"the":[12,40,44,48,56,72,86,90,118,127,153,181,201],"pharmacokinetic":[13],"and":[14,38,69,77,89,103,110,150,170,189,193,213],"pharmacodynamic":[15],"properties":[16],"of":[17,29,66,100,205],"a":[18,122,175],"lipid-based":[19],"(soft":[20],"gelatin":[21],"capsule)":[22],"prototype":[23],"final":[24],"market":[25],"image":[26],"(pFMI)":[27],"formulation":[28,120],"tropifexor":[30],"(90-\u00b5g)":[31],"to":[32,163,207],"its":[33],"clinical":[34],"service":[35],"form":[36],"(CSF)":[37],"assessed":[39],"food":[41,81,208],"effect":[42,82],"for":[43,55,62,85,94,126,168,172],"pFMI":[45,63,87,95,98,190,197],"formulation.":[46],"In":[47],"fasted":[49,99,135,192],"state,":[50],"drug":[51,148],"exposure":[52],"was":[53,83,184],"higher":[54,123],"pFMI.":[57],"The":[58,196],"geometric":[59,91],"mean":[60,92],"ratios":[61,93],"versus":[64,97],"CSF":[65,119,169,187,202],"peak":[67,101],"concentration":[68,102,146],"area":[70,104,151],"under":[71,105,152],"concentration-time":[73,106,158],"curve":[74,107,159],"were":[75,108,166],"2.0":[76],"1.5,":[78],"respectively.":[79,112],"No":[80],"apparent":[84],"formulation,":[88],"fed":[96,194],"1.0":[109,111],"Despite":[113],"having":[114],"lower":[115,210],"systemic":[116],"exposure,":[117],"provided":[121],"pharmacological":[124,182],"response":[125],"gut":[128],"biomarker":[129],"fibroblast":[130,137],"growth":[131,138],"factor":[132,139],"19.":[133],"Under":[134],"conditions,":[136],"19":[140],"maximum":[141],"change":[142,154],"from":[143,155,160],"baseline":[144,156],"serum":[145,157,178],"after":[147],"administration":[149],"time":[161],"0":[162],"24":[164],"hours":[165],"36%":[167],"12%":[171],"FMI.":[173],"For":[174],"second":[176],"biomarker,":[177],"7-alpha":[179],"hydroxy-4-cholest-3-one,":[180],"activity":[183],"comparable":[185],"between":[186],"(fasted)":[188],"(both":[191],"states).":[195],"offers":[198],"advantages":[199],"over":[200],"terms":[204],"insensitivity":[206],"effect,":[209],"intersubject":[211],"variability,":[212],"overcoming":[214],"solubility":[215],"limitations.":[216]},"counts_by_year":[],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2022-12-22T00:00:00"}